- $165.86bn
- $228.49bn
- $58.50bn
- 58
- 59
- 87
- 75
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 10.49 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | -0.37% | ||
Dividend Yield (f) | 5.85% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.89 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 34.48 | ||
Price to Sales | 2.98 | ||
EV to EBITDA | 111.13 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -2.69% | ||
Return on Equity | -2.75% | ||
Operating Margin | -8.34% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 41,172 | 41,651 | 81,288 | 100,330 | 58,496 | 61,193.24 | 63,232.82 | 7.46% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +17.12 | +18.34 | +252.05 | +22.76 | -49 | -17.75 | +8.39 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
Directors
- Albert Bourla CHM (59)
- Angela Hwang CEX (55)
- Payal Sahni CHO (46)
- Lidia Fonseca EVP (52)
- Rady Johnson EVP (59)
- Douglas Lankler EVP (55)
- William Carapezzi EVP
- Alexander Mackenzie EVP (61)
- Aamir Malik EVP
- Mike Mcdermott EVP
- Sally Susman EVP (59)
- Christopher Stevo SVP
- Mikael Dolsten CSO (63)
- Shantanu Narayen LED (57)
- Ronald Blaylock IND (61)
- Susan Desmond-Hellmann IND (63)
- Joseph Echevarria IND (64)
- Scott Gottlieb IND (48)
- William Gray IND
- Helen Hobbs IND (68)
- Susan Hockfield IND (70)
- Dan Littman IND (68)
- Suzanne Nora Johnson IND (64)
- James Quincey IND (56)
- James Smith IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 2nd, 1942
- Public Since
- January 17th, 1944
- No. of Shareholders
- 123,387
- No. of Employees
- 88,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 5,666,695,064
- Address
- 66 HUDSON BOULEVARD EAST, NEW YORK, 10001-2192
- Web
- https://www.pfizer.com/
- Phone
- +1 2127332323
- Auditors
- KPMG LLP
Latest News for PFE
Upcoming Events for PFE
Q3 2024 Pfizer Inc Earnings Release
Q4 2024 Pfizer Inc Earnings Release
Similar to PFE
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 23:05 UTC, shares in Pfizer are trading at $29.27. This share price information is delayed by 15 minutes.
Shares in Pfizer last closed at $29.27 and the price had moved by -14.29% over the past 365 days. In terms of relative price strength the Pfizer share price has underperformed the S&P500 Index by -32.2% over the past year.
The overall consensus recommendation for Pfizer is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Pfizer dividend yield is 5.67% based on the trailing twelve month period.
Last year, Pfizer paid a total dividend of $1.66, and it currently has a trailing dividend yield of 5.67%. We do not have any data on when Pfizer is to next pay dividends.
We do not have data on when Pfizer is to next pay dividends. The historic dividend yield on Pfizer shares is currently 5.67%.
To buy shares in Pfizer you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $29.27, shares in Pfizer had a market capitalisation of $165.86bn.
Here are the trading details for Pfizer:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: PFE
Based on an overall assessment of its quality, value and momentum Pfizer is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pfizer is $33.01. That is 12.78% above the last closing price of $29.27.
Analysts covering Pfizer currently have a consensus Earnings Per Share (EPS) forecast of $2.64 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pfizer. Over the past six months, its share price has underperformed the S&P500 Index by -4.11%.
As of the last closing price of $29.27, shares in Pfizer were trading +4.07% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pfizer PE ratio based on its reported earnings over the past 12 months is 10.49. The shares last closed at $29.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pfizer's management team is headed by:
- Albert Bourla - CHM
- Angela Hwang - CEX
- Payal Sahni - CHO
- Lidia Fonseca - EVP
- Rady Johnson - EVP
- Douglas Lankler - EVP
- William Carapezzi - EVP
- Alexander Mackenzie - EVP
- Aamir Malik - EVP
- Mike Mcdermott - EVP
- Sally Susman - EVP
- Christopher Stevo - SVP
- Mikael Dolsten - CSO
- Shantanu Narayen - LED
- Ronald Blaylock - IND
- Susan Desmond-Hellmann - IND
- Joseph Echevarria - IND
- Scott Gottlieb - IND
- William Gray - IND
- Helen Hobbs - IND
- Susan Hockfield - IND
- Dan Littman - IND
- Suzanne Nora Johnson - IND
- James Quincey - IND
- James Smith - IND